Caris Life Sciences (NASDAQ:CAI) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Caris Life Sciences (NASDAQ:CAI – Free Report) from a buy rating to a hold rating in a report published on Saturday morning.

Caris Life Sciences Price Performance

CAI stock opened at $28.86 on Friday.

Caris Life Sciences Company Profile

(Get Free Report)

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.

See Also

• Five stocks we like better than Caris Life Sciences
• How to Use the MarketBeat Dividend Calculator
• Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
• Why Are These Companies Considered Blue Chips?
• Gates Foundation Sells MSFT Stock—Should Investors Be Worried?
• Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
• MarketBeat Week in Review – 12/1 – 12/5